secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2026-09-22T20:05:55+00:00
Accession:  0001437749-26-030900
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu Q4 FY26 revenue up 6.4% to $16.1M; EXXUA launches with 3,323 scripts
-------------------------------------------------------------------------

- Q4 FY26 net revenue $16.1M, +6.4% YoY; EXXUA alone contributed $3.9M in first full quarter.
- EXXUA Q4 prescriptions 3,323, up ~138% from Q3; June hit record 1,261 scripts; shipments ~4,600 units.
- Full-year FY26 revenue $57.6M, down 13.3% YoY, driven by ADHD portfolio decline and Adzenys generic competition.
- FY26 net loss $14.3M ($1.16 loss/share) vs $13.6M loss; Adjusted EBITDA -$3.7M vs +$9.2M prior year.
- Cash $26.3M at June 30, 2026; warrant amendment cut derivative warrant liabilities by $26.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774926030900/0001437749-26-030900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774926030900/aytu20260502_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-030900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer